uiring treatment Novo Nordisk ® Distribution of patients and value across treatment classes 100% 80% 44% 60% 40% 20% 18% 4% 8% 26% 0% Patients Insulin SGLT-2i er: metformin, sulfonylurea, thiazolidinediones. GLP-1 Inj. DPP-IV 4% 16% 16% 1% 24% 38% Value Oral GLP-1 Trad. OAD
Download PDF file